Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Scribe Therapeutics Inc.Eli Lilly
Last price
$15.48$1,364.73
Currency
USD
USD
$293M$1.2T
-44.29
-$13.18$30.81
-0.39
0$6.69
00.51%
Sector
HealthHealth
Employees
8250,000
Ticker
$SCTX$LLY
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $SCTX or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.